- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Wanbury Limited — Updates, 13-08-2026: Press Release
13-08-2026 | 12:44 pm
13-08-2026 | 12:44 pm
Wanbury secured EDQM approval for Rivaroxaban API, boosting EU market access. The company also received USFDA DMF clearances for Paraxetine HCl and Metformin HCl, strengthening its product pipeline and reach for customers.
No comments yet. Be the first to comment!